Achieve Life Sciences, Inc. (ACHV): Price and Financial Metrics


Achieve Life Sciences, Inc. (ACHV): $8.24

0.07 (+0.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ACHV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 465

in industry

ACHV Stock Price Chart Interactive Chart >

Price chart for ACHV

ACHV Price/Volume Stats

Current price $8.24 52-week high $16.10
Prev. close $8.17 52-week low $6.55
Day low $8.06 Volume 8,645
Day high $8.35 Avg. volume 45,157
50-day MA $7.70 Dividend yield N/A
200-day MA $8.35 Market Cap 77.89M

Achieve Life Sciences, Inc. (ACHV) Company Bio


Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.


ACHV Latest News Stream


Event/Time News Detail
Loading, please wait...

ACHV Latest Social Stream


Loading social stream, please wait...

View Full ACHV Social Stream

Latest ACHV News From Around the Web

Below are the latest news stories about Achieve Life Sciences Inc that investors may wish to consider to help them evaluate ACHV as an investment opportunity.

Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference

SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will give a presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The conference is taking place virtually from January 10 - 13, 2022. Details for access to the presentation are as follows: H.C. Wainwright BIOCONNECT Virtual Conference: Date: January 10, 2022 Time: 7:00 am ET Investors can register for the conference HERE . Following the conference, a webcast replay of the presentation will be available on Full story available on Benzinga.com

Benzinga | January 6, 2022

Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation

Topline ORCA-2 Results Expected in Q2 2022SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the last study follow-up visit for the last subject enrolled in the ORCA-2 Phase 3 trial occurred in late December 2021. The ORCA-2 trial is the first

Yahoo | January 4, 2022

Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Development

SEATTLE and VANCOUVER, British Columbia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into a $25 million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. ("SVB"). The proceeds and funds available under the debt agreement are expected to fund the completion of the cytisinicline smoking cessation clinical development program. As part of the contingent convertible debt agreement, SVB will fund $15 million in the form of convertible indebtedness to Achieve at closing on December 22, 2021. Subject to the terms and conditions of the ...

Benzinga | December 22, 2021

Achieve Life Sciences Secures $25M Loan Facility To Fund Smoking Cessation Program

Achieve Life Sciences Inc (NASDAQ: ACHV) has entered into a million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. The proceeds and funds available under the debt agreement are expected to fund the completion of the cytisinicline smoking cessation clinical development program. Related: Achieve Life Sciences To Start Cytisinicline's Trial For Nicotine E-cigarette Cessation. As part of the contingent convertible debt agreement, SVB will fund $15 million in the fo

Yahoo | December 22, 2021

Geode Capital Management LLC Purchases 27,379 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV)

Geode Capital Management LLC grew its position in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 93.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,669 shares of the biopharmaceutical companys stock after acquiring an additional 27,379 shares []

Transcript Daily | November 27, 2021

Read More 'ACHV' Stories Here

ACHV Price Returns

1-mo 11.50%
3-mo 1.35%
6-mo 5.91%
1-year -18.09%
3-year -69.02%
5-year -99.32%
YTD 5.91%
2021 -3.95%
2020 -23.57%
2019 -56.21%
2018 -90.97%
2017 -75.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8011 seconds.